Bristow Group Inc (BRS) Jumps 11.68% on February 16

Equities Staff |

Bristow Group Inc (BRS) was among the biggest gainers on the Russell 2000 for Tuesday February 16 as the stock popped 11.68% to $14.25, representing a gain of $1.49 per share. Some 1.42 million shares traded hands on 7,531 trades, compared with an average daily volume of 792,145 shares out of a total float of 34.95 million. The stock opened at $13.32 and traded with an intraday range of $15.32 to $13.22.

After today's gains, Bristow Group Inc reached a market cap of $498.06 million. Bristow Group Inc has had a trading range between $64.64 and $11.02 over the last year, and it had a 50-day SMA of $22.46 and a 200-day SMA of $37.21.

Bristow Group Inc is a provider of helicopter services to the offshore energy industry based on the number of aircraft operated and one of two helicopter service providers to the offshore energy industry with global operations.

Bristow Group Inc is based out of Houston, TX and has some 5,232 employees. Its CEO is Jonathan E. Baliff.

For a complete fundamental analysis analysis of Bristow Group Inc, check out Equities.com’s Stock Valuation Analysis report for BRS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Cloudera

Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…